Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plethora Solutions Holdings has completed recruitment into the European arm of a Phase III study of PSD502 for the treatment of premature ejaculation in Europe. The study was initiated in December 2007 and results are expected before the end of 2008.
Subscribe to our email newsletter
There are two pivotal studies running in parallel, one in North America and one in Europe. Each is a multicenter, randomized, double-blind, placebo-controlled efficacy study recruiting a total of 540 patients across both studies. In the European arm, 333 patients have been recruited by 32 investigational centers in four countries across Europe. Patients are being treated for a 12-week period with an optional five-month open-label phase.
The primary endpoints will be intravaginal ejaculation latency time, sexual satisfaction and ejaculatory control. Secondary endpoints will include sexual quality of life and partner satisfaction.
PSD502 is a proprietary formulation of two marketed drugs, lidocaine and prilocaine, dispensed by a metered dose aerosol developed for the treatment of premature ejaculation, a disorder affecting up to 30% of men in Europe and the US, according to the company.